SSRI monitoring form for a primary care pediatric nurse practitioner
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
FDA notifies providers of safety-related changes to prescribing information of maralixibat, odevixibat
The updated labeling includes a new contraindication for patients with prior or active hepatic events.
Food Insecurity and the Dangers of Infant Formula Dilution
New 2022 data: Pediatric mental health hospitalizations decline overall, increase for females
The total number of pediatric mental health hospitalizations declined in 2022, the first time observed since 2009.
Demystifying Infant Formula
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis
Roflumilast cream 0.05% is being studied for mild-to-moderate AD in infants aged 3 months to under 2 years in a new phase 2 trial.
Marstacimab reduces ABR in patients 12 years and up with hemophilia A or B with inhibitors
New phase 3 data support marstacimab’s efficacy and safety in treating hemophilia A or B with inhibitors, expanding its potential use.